Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GlaxoSmithKline plc announced its decision to stop the MAGRITi trial,…
2 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients...